DeutschNewstral
Article
bizjournals.com on 2021-03-31 18:38
Jennifer Doudna’s Scribe Therapeutics lands a $100M Series B to advance CRISPR technology
Related news
- Jennifer Doudna’s Scribe Therapeutics lands a $100M Series B to advance CRISPR technologybizjournals.com
- CRISPR startup Scribe Therapeutics lands big Biogen dealbizjournals.com
A New Approach To CRISPR - Scribe Therapeutics Designs Novel CRISPR MoleculesForbes- CRISPR gene editing startup Beam Therapeutics plans $100M IPObizjournals.com
Crispr Therapeutics Plans to Launch Its First Clinical Trial in 2018Wired.com- Main Line's Aclipse Therapeutics lands $720K from Australia research firm to advance ALS therapybizjournals.com
- MCrispr Therapeutics files for $90 million IPOmarketwatch.com
News24 | Tatjana sets pace for 100m Olympic podium, Coetze lands African record to advanceNews24- Werewolf Therapeutics files for $100M IPObizjournals.com
Orphan Drug Exclusivity for CRISPR/Cas-Based Therapeuticsjdsupra.com- BCRISPR Therapeutics Is Upgraded After $900 Million Dealbarrons.com
SDG&E SEEKING $100M IN FEDERAL FUNDS TO ADVANCE WILDFIRE SAFETY EFFORTS ON OR NEAR TRIBAL LANDSeastcountymagazine.org- BCrispr Therapeutics Stock Spikes on Positive Gene-Editing Resultsbarrons.com
- CRISPR Therapeutics stock jumps on early gene editing databizjournals.com
WTF is CRISPR?TechCrunch- Alabama company lands $100M projectbizjournals.com
- Longwood Fund-founded TScan Therapeutics files for $100M IPObizjournals.com
Seattle biotech firm Silverback Therapeutics aims for $100M IPOSeattle Times- NAdvance improves cutting and pasting with CRISPR-Cas9 gene editingnews.berkeley.edu
- BVertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR Therapeuticsbarrons.com